BioCentury
ARTICLE | Clinical News

Subcutaneous GSK3196165: Phase II started

April 25, 2016 7:00 AM UTC

GlaxoSmithKline began a double-blind, placebo-controlled, European Phase II trial to evaluate 8 injections of subcutaneous GSK3196165 over 12 weeks in 40 patients. GSK has exclusive, worldwide rights ...